Hospira enrolls first patient in biosimilar trial

Phase-3 trial to compare biosimilar erythropoietin with Amgen's Epogen
Generic drug maker Hospira has enrolled the first patient in a late-stage clinical trial of a biosimilar drug for treating kidney disease.

Want to Read More?

This content is available only to registered users. Log in to read the rest of this article or create a free account.

neutroppenia caused by cancer

neutroppenia caused by cancer drugs!! This is a case where the operation was a success"but the patient died".My late daughter inlaw (succuimbed to brain cancer) was given the "poly cocktail of cancer drugs-and including gamma ray directly to the brain.My dear friend (still surviving)after heavy dosing of anti cancer drugs for breast cancer-now has heart disease,copd,brittle teeth,arthritis--this poly pharmacy of cancer drugs has to be re-examined and more thoroughly evaluated.

© 2012 Drug Store News. All Rights Reserved.